Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients.

Front Cardiovasc Med · 2022 · PMC9113403 · PMID 35592406

Europe PMC DOI

hedged sentence

0.0210

closest p · 0.4× alpha

0.0210

boldest claim

The sentences

slightly significantp = 0.021actually significant

At the same time, an RV echocardiography performed at 6 months revealed slightly significant reduction in TRV ( p = 0.021) and estimated PASP ( p = 0.022) but not in tricuspid regurgitation ( p = 0.166).

also in 1,762 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.